Otsuka’s Half-Year Pharma Sales Up 4.1% on Global Brands

Otsuka Holdings’ pharmaceutical segment sales in January-June grew 4.1% year on year as upbeat global brands more than offset the impact of Japan’s biennial price revision in April, which particularly hit its off-patent drugs Abilify (aripiprazole), Pletaal (cilostazol), and Mucosta...read more